FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	. 0.5									

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative
intended to satisfy the affirmative
defense conditions of Rule 10b5-

1(c). Se	ee Instruction 1	0.																		
Name and Address of Reporting Person* Hirano Patricia C				2. Issuer Name and Ticker or Trading Symbol SOLENO THERAPEUTICS INC [SLNO]										Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) 100 MARINE PARKWAY, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year)										V	Officer (give title below) SEE REMARKS				
100 MAI	RINE PARI	KWAY, SUITE 4	00																	
(Street) REDWOOD CITY CA 94065		5	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line)	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City)	(St	ate) (Ž	Zip)																	
		Table	1 - 1	Non-Deriva	tive	Secu	rities	Acc	uire	ed, C	Disp	osed o	f, or E	Benefi	cially	Own	ed			
Date			2. Transaction Date (Month/Day/Ye	Execution Da		n Date	, Tr	3. Transaction Code (Instr. 8)						d 5)	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								C	ode	v	Amo	ount	(A) or (D)	Price		Transa	action(s) 3 and 4)	(inst	(r. 4)	(Instr. 4)
Common Stock 10/01/202				4		S	$S^{(1)}$		2	,789	D	D \$49.3358		2) 109,251(3)		D				
Common Stock 10/01/202				.4		S	S ⁽¹⁾		3	319	D	\$50.2	479 ⁽⁴⁾	108,932(3)		D				
		Tal	ole	II - Derivati (e.g., ρι)wne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) i	Exe if a			saction e (Instr.	5. Num of Derive Secur Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired osed	Exp	iration	xercisable and n Date ay/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Deri Sec (Ins	ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Natur of Indired Beneficia Ownersh (Instr. 4)
									Date		Expiration			or Number	r					

Explanation of Responses:

1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

Code V

2. This transaction was executed in multiple trades at prices ranging from \$48.95 to \$49.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price

(A) (D) Exercisable Date

- 3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- 4. This transaction was executed in multiple trades at prices ranging from \$49.95 to \$50.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Remarks:

Officer title: Senior Vice President, Regulatory Affairs

/s/ Anish Bhatnagar, Attorney-10/03/2024 in-Fact

Title Shares

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.